Enjaymo is an immunoglobulin G subclass 4 monoclonal antibody.
All articles by Diana Ernst, RPh
The approval was based on data from the KEYNOTE-091 trial.
Recent data show that the product is unlikely to be active against currently circulating SARS-CoV-2 variants.
It was originally approved in 2019 for the treatment of chronic pain.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
The CD20-directed cytolytic antibody therapy was approved based on data from two phase 3 trials.
The pembrolizumab combination was not associated with an improvement in overall survival or radiographic progression-free survival.
Rezafungin is an investigational echinocandin antifungal that is administered once weekly.
Odactra is an allergen extract indicated as immunotherapy for the treatment of HDM-induced allergic rhinitis.
The prescription-only device works with integrated continuous glucose monitors and alternate controller enabled pumps.
Latest News Your top articles for TuesdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses